Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel - proton pump inhibitor interaction.

Kruik-Kollöffel, Willemien J; van der Palen, Job; Kruik, H Joost; van Herk-Sukel, Myrthe P P; Movig, Kris L L

Kruik-Kollöffel, Willemien J; van der Palen, Job; Kruik, H Joost; van Herk-Sukel, Myrthe P P; Movig, Kris L L.

Afiliación

Kruik-Kollöffel WJ; Department of Clinical Pharmacy Medisch Spectrum Twente Enschede The Netherlands; Present address: Department of Clinical Pharmacy Saxenburgh Group Hardenberg The Netherlands.
van der Palen J; Medical School Twente Medisch Spectrum Twente Enschede The Netherlands; Department of Research Methodology, Measurement and Data Analysis University of Twente Enschede The Netherlands.
Kruik HJ; Department of Cardiology Hospital Group Twente Almelo and Hengelo The Netherlands.
van Herk-Sukel MP; Pharmo Institute Utrecht The Netherlands.
Movig KL; Department of Clinical Pharmacy Medisch Spectrum Twente Enschede The Netherlands.

Pharmacol Res Perspect ; 4(4): e00242, 2016 08.

Article en En | MEDLINE | ID: mdl-28116095

Palabras clave

Antiulcer agents; clopidogrel; drug interactions; drug safety; histamine H2 antagonists; pharmacoepidemiology; pharmacovigilance; proton pump inhibitors; risk assessment; risk factors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Pharmacol Res Perspect Año: 2016 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google